Weekly Digest – April 2026 Weekly Digest – April 2026 20 April 2026: Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma GSK has announced that China’s NMPA has approved Blenrep in combination with bortezomib and dexamethasone for […]
Weekly Digest – April 2026 Weekly Digest – April 2026 20 April 2026: U.S. FDA grants Priority Review to sBLA for PADCEV + Keytruda as perioperative treatment for MIBC regardless of Cisplatin eligibility U.S. Food and Drug Administration has granted […]
Weekly Digest – April 2026 Weekly Digest – April 2026 22 April 2026: Trastuzumab Ruikang has received BTD from China’s NMPA for the treatment of HER2‑positive breast cancer Jiangsu Hengrui Pharmaceuticals announced that its HER2-targeting ADC Trastuzumab Ruikang in combination […]
Weekly Digest – April 2026 Weekly Digest – April 2026 22 April 2026: SHR‑A2102 has received BTD from China’s NMPA for the treatment of cervical cancer Jiangsu Hengrui Pharmaceuticals announced that its SHR-A2102 ADC has been granted Breakthrough Therapy Designation […]
Weekly Digest – April 2026 Weekly Digest – April 2026 23 April 2026: Mabwell initiates phase 3 clinical study of its Nectin-4 targeting ADC 9MW2821 for the treatment of TNBC Mabwell announced the initiation of a Phase 3 clinical trial […]
Weekly Digest – April 2026 Weekly Digest – April 2026 23 April 2026: Servier completes the acquisition of Day One Biopharmaceuticals Servier has completed the acquisition of Day One Biopharmaceuticals in a deal valued at approximately $2.5 billion, strengthening its […]
